With $3.2M, DioGenix Planning Prospective Trial Completion in 2014, CLIA Bid for MS Sequencing Test | GenomeWeb

DioGenix plans to use $3.2 million raised in a private financing earlier this month to support the ongoing prospective clinical trial of its targeted next-generation sequencing-based multiple sclerosis test, MS Precise.

In addition, the Gaithersburg, Md.-based company has established a new central lab facility, for which it plans to seek CLIA certification to commercialize MS Precise as a laboratory-developed test.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.